Elsevier

Placenta

Volume 34, Issue 4, April 2013, Pages 369-373
Placenta

The transfer of ethyl glucuronide across the dually perfused human placenta

https://doi.org/10.1016/j.placenta.2012.12.016Get rights and content

Abstract

Introduction

Alcohol consumption during pregnancy can lead to Fetal Alcohol Spectrum Disorder (FASD), and because maternal self-reports are often unreliable, biomarkers of alcohol use are sometimes necessary to accurately determine fetal risk. Ethyl glucuronide (EtG), a direct metabolite of ethanol, has been detected in the meconium of infants born to mothers who consumed excessive alcohol during pregnancy. It is still unknown whether EtG detected in meconium originated from maternal hepatic glucuronidation of ethanol followed by subsequent placental transfer. Therefore, the objective of this study was to determine if EtG crosses the human placenta.

Methods

The transfer of EtG was measured using the ex vivo dual perfusion of an isolated human placental lobule. EtG (1 μg/mL) was added to the maternal circulation and samples were taken throughout the 1 h pre-experimental and 3 h experimental phases for measurement of EtG and markers of placental viability.

Results

After 3 h, the fetal-to-maternal ratio was 0.29 ± 0.02 and net maternal-to-fetal transfer was still occurring. Triplicate averages of EtG concentrations in perfused placental lobules ranged from 140 to 414 ng/g tissue. Placental validation markers were within normal ranges for all perfusions.

Discussion

The data show that EtG crosses the human placenta and primarily represents maternal exposure to alcohol.

Conclusions

This information can help with the development of more thorough biomarker screens for alcohol use during pregnancy.

Introduction

Determining the extent of fetal exposure to alcohol during pregnancy can help identify the risk of Fetal Alcohol Spectrum Disorder (FASD) in newborns. FASD is the leading preventable cause of malformations, intellectual disabilities, and neurobehavioral disorders in the Western world [1]. Left untreated, individuals with FASD can develop secondary characteristics, such as mental health issues, addictions, and trouble with the law [2]. As such, it is of vital importance for healthcare providers to adequately screen for maternal use of and fetal exposure to alcohol to help identify high-risk cases.

While confirmed alcohol use during pregnancy is the best indicator of fetal risk for FASD, many women under-report their consumption due to fear of stigmatization and blame [3]. For this reason, ethanol metabolites such as fatty acid ethyl esters (FAEE) are often used as objective biomarkers of fetal alcohol exposure. FAEEs have been detected in maternal hair and neonatal meconium, which begins to form at 12 weeks gestation. They were also shown to not cross the human placenta and therefore are biomarkers of direct fetal exposure to ethanol [4]. Despite these findings, there are several sources of false results with FAEE analysis, such as prenatal vitamin use, olive oil use, and contamination of meconium with post-natal stool [5], [6]. These sources of false results warrant investigation into other biomarkers that could supplement FAEE analysis.

Similar to FAEE, ethyl glucuronide (EtG) is a minor, direct, non-oxidative metabolite of ethanol. EtG is formed by the net addition of UDP-glucuronic acid to ethanol, a reaction catalyzed by the UDP-glucuronosyl transferase (UGT) family [7]. Compared to ethanol, EtG is stable within the body for longer periods and can therefore provide a larger window of alcohol consumption. With respect to pregnant patients, EtG has previously been detected in maternal hair [8], neonatal meconium [3], [9], [10], [11], as well as first trimester placental tissue and fetal remains [12]. Recently, a cut-off of 2 nmol/g has been established in meconium to differentiate excessive alcohol consumption during pregnancy [10]. These findings suggest that EtG could be a useful supplemental biomarker to FAEEs to help improve screening accuracy.

Whether EtG detected in these matrices is of maternal or fetal origin needs to be determined, since the EtG cut-off in meconium may depend on the relative contributions of these factors. While EtG is extensively formed in the adult liver [7], no studies have investigated fetal hepatic ethanol glucuronidation. Several reports have indicated that, compared to the adult liver, glucuronidation is greatly reduced in the fetus and only begins to develop postpartum [13], [14]. If, like FAEEs, EtG does not cross the placenta, then EtG detected in meconium is solely of fetal origin. However, it is much more likely that there is transfer, in which case EtG is primarily of maternal origin with a potentially minor fetal contribution. To help clarify the utility of EtG in alcohol screens, the objective of this study was to determine if physiologically relevant levels of EtG cross the human placenta.

Section snippets

Ex vivo perfusion of a single placental cotyledon

The ex vivo placental perfusion model has been previously explained in detail [15] and adapted in our laboratory [16], [17]. Term placentae were obtained from scheduled elective Caeserian sections at the obstetrics ward at St. Michael's Hospital in Toronto, Ontario, Canada. Research ethics board approval was obtained from the hospital and mothers gave written consent prior to delivery. Immediately after delivery, placentae were transported to the on-site perfusion laboratory in ice-cold

Results

A total of 4 cotyledons from different placentae were perfused with 1 μg/mL EtG and mean lobule weight of the 4 perfused lobules was 19.03 ± 1.29 g. Maternal and fetal flow rates were 13.65 ± 0.68 and 2.11 ± 0.06 mL/min, respectively. Parameters of placental integrity and viability are presented in Table 1. None of the parameters were statistically different between the control and experimental phases. Antipyrine equilibrated between the two circulations after 3 h with a final mean F:M ratio of

Discussion

The results of this perfusion study show that EtG crosses the term human placenta slowly, reaching an F:M ratio of 0.29 after 3 h of perfusion. Glucuronide metabolites have previously been shown to cross the placenta, resulting in significant fetal concentrations [24], [25]. In pregnant baboons injected with morphine-3-glucuronide, F:M ratios of 0.7–0.9 were measured after 24 h, by which point the metabolite was presumably at steady state [25]. The final F:M ratio of 0.29 is likely not

Acknowledgments

The authors would like to thank the generous staff at St. Michael's Hospital for facilitating sample collection. This study is supported by a grant from the Canadian Institutes for Health Research and the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation. JNM is supported by an Ontario Graduate Scholarship. GK is the holder of the Ivey Chair in Molecular Toxicology, The Department of Medicine, University of Western Ontario.

References (36)

  • P. Myllynen et al.

    ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta

    Toxicol Appl Pharmacol

    (2008)
  • L. Krivankova et al.

    Analysis of ethyl glucuronide in human serum by capillary electrophoresis with sample self-stacking and indirect detection

    J Chromatogr A

    (2005)
  • M. Nishimura et al.

    Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes

    Drug Metab Pharmacokinet

    (2006)
  • A.C. Collier et al.

    UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term

    Biochem Pharmacol

    (2002)
  • A.P. Streissguth

    Fetal alcohol syndrome: a guide for families and communities

    (1997)
  • A. Bakdash et al.

    Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study

    Anal Bioanal Chem

    (2010)
  • D. Chan et al.

    Placental handling of fatty acid ethyl esters: perfusion and subcellular studies

    J Pharmacol Exp Ther

    (2004)
  • D. Chan et al.

    Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto

    Ther Drug Monit

    (2003)
  • Cited by (14)

    • Biomarkers of Toxicity in Human Placenta

      2019, Biomarkers in Toxicology
    • Meconium biomarkers of prenatal alcohol exposure

      2019, Neuroscience of Alcohol: Mechanisms and Treatment
    • Placental control of drug delivery

      2017, Advanced Drug Delivery Reviews
      Citation Excerpt :

      Ethanol can be partially oxidized to acetaldehyde by CYP2E1 and it can also be conjugated to glucuronide to make ethyl glucuronide. This compound can cross the placenta but it is not yet clear whether this is mediated by placental UGT2B7 [126]. UGT1A4 is responsible for lamotrigine glucuronidation.

    • Rivaroxaban transfer across the dually perfused isolated human placental cotyledon

      2015, American Journal of Obstetrics and Gynecology
      Citation Excerpt :

      Lactate production remained constant for the duration of the perfusion. For all perfusions, antipyrine equalized between the maternal and fetal reservoirs after 3 hours with a final fetal-to-maternal ratio of 0.84 (interquartile range [IQR], 0.76–0.88), which is comparable with previous perfusion experiments.13-16 The rate of antipyrine disappearance from the maternal circulation was equal to the rate of appearance in the fetal circulation: 0.025 (IQR, 0.015–0.031) vs 0.023 (IQR, 0.014–0.029) μmol/g/min (P = .77).

    • Antiretroviral Drugs in Meconium: Detection for Different Gestational Periods of Exposure

      2015, Journal of Pediatrics
      Citation Excerpt :

      Placental transfer of AZT was previously shown to be high17 and AZT pharmacokinetic studies in pregnant baboons and monkeys indicated similar maternal and fetal AZT-glucuronide/AZT ratios and AZT-glucuronide plasma concentrations following maternal steady-state AZT infusion.27,28 These data suggest maternal AZT-glucuronide is effectively transferred across the placenta as previously reported for other glucuronides.29,30 Fetal glucuronidation capacity is generally limited, but increases during a neonate's first 3 months are log-linear until adult levels are achieved.31

    • Biomarkers of toxicity in human placenta

      2014, Biomarkers in Toxicology
    View all citing articles on Scopus
    View full text